MAPK
Le MAPK sono una famiglia di chinasi proteiche coinvolte in una varietà di processi cellulari, tra cui crescita, proliferazione, differenziazione e risposte allo stress. La via di segnalazione MAPK è composta da diversi livelli, tra cui ERK, JNK e p38 MAPK, ciascuno con ruoli distinti nella funzione cellulare. La disregolazione della segnalazione MAPK è collegata al cancro, alle malattie infiammatorie e ai disturbi metabolici. Presso CymitQuimica, offriamo una vasta gamma di inibitori e attivatori delle MAPK per supportare la tua ricerca in biologia cellulare, trasduzione del segnale e meccanismi delle malattie.
Trovati 893 prodotti di "MAPK"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK3-IN-13
JAK3-IN-13: Oral JAK3 inhibitor, selective & potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.Formula:C25H33ClN6O5Colore e forma:SolidPeso molecolare:533.02pan-KRAS degrader 1
CAS:<p>Pan-KRAS degrader 1 (Compound 1) is a broad-spectrum KRAS degrader, exhibiting an inhibitory constant Ki value of 25 nM against KRASG12V as determined by surface plasmon resonance (SPR). Additionally, this compound demonstrates antitumor activity.</p>Formula:C22H26N8OSColore e forma:SolidPeso molecolare:450.56KRASG12C IN-13
CAS:KRASG12C IN-13 (LY3499446), a potent inhibitor of KRAS G12C, shows potential in the study of advanced solid tumors, specifically non-small cell lung cancer and colorectal cancer.Formula:C22H17ClF2N6OSColore e forma:SolidPeso molecolare:486.93EBI-1051
CAS:EBI-1051 is a highly potent and orally efficacious inhibitor of MEK (IC50: 3.9 nM).Formula:C18H15F2IN2O5Purezza:98%Colore e forma:SolidPeso molecolare:504.22KRAS inhibitor-13
CAS:KRAS inhibitor-13 blocks KRAS G12C (IC50: 0.883 μM) and p-ERK in some cancer cells; promising for pancreatic, colorectal, lung cancer research.Formula:C25H19ClFN3O2SColore e forma:SolidPeso molecolare:479.95JH295 hydrate
JH295 hydrate: potent, irreversible Nek2 inhibitor (IC50 = 770 nM), selective, doesn't target Cdk1, Aurora B or Plk1.Formula:C18H18N4O3Colore e forma:SolidPeso molecolare:338.36KRAS G12D inhibitor 16
CAS:<p>KRAS G12D inhibitor 16 targets KRAS G12D with IC50 of 0.7 nM and mutant form at 0.35 μM, useful in various cancer studies.</p>Formula:C32H39IN6O3Colore e forma:SolidPeso molecolare:682.59AMG-548 hydrochloride
AMG-548 hydrochloride: orally active, p38α inhibitor (Ki=0.5 nM), 1000x less for p38γ/δ, also blocks TNFα (IC50=3 nM) & inhibits casein kinase 1 δ/ε.Formula:C29H28ClN5OColore e forma:SolidPeso molecolare:498.02SHR902275
CAS:SHR902275: potent RAF inhibitor, hits RAS mutations, oral use. cRAF IC50=1.6 nM, bRAFwt IC50=10 nM, bRAFV600E IC50=5.7 nM, hinders cell growth.Formula:C26H23F3N4O4Colore e forma:SolidPeso molecolare:512.48G-479
CAS:<p>G-479, a potent MEK inhibitor and improved analogue of GDC-0623, has distributed polarity enhancing bioactivity.</p>Formula:C16H15FIN5O4Colore e forma:SolidPeso molecolare:487.22(+)-Perillyl alcohol
CAS:(+)-Perillyl alcohol (0.25-1 mM) inhibits cell growth in SW480 cells. At a concentration of 1 mM and a duration of 24 hours, (+)-Perillyl alcohol increases the number of cells in the G0/G1 phase and reduces the number in the S phase in SW480 cells.Formula:C10H16OColore e forma:SolidPeso molecolare:152.23ERK1/2 inhibitor 6
CAS:ERK1/2 inhibitor 6 - potent cancer/inflammation treatment from WO2021063335A1.Formula:C27H29ClFN7O5Colore e forma:SolidPeso molecolare:586.01RSK4-IN-1
CAS:RSK4-IN-1 is a compound exhibiting potent inhibition of RSK4, demonstrated by an IC50 value of 9.5 nM.Formula:C19H20F2N4O3Colore e forma:SolidPeso molecolare:390.38NHTD
CAS:NHTD, a KRAS-PDEδ inhibitor, exerts its function by targeting the isoprenyl binding pocket of PDEδ, which alters the cellular localization of KRAS. This modification restricts the proliferation of cancer cells with KRAS mutations and induces cell apoptosis (Apoptosis). NHTD is utilized in the study of KRAS-driven non-small cell lung cancer (NSCLC).Formula:C24H26N2O5Colore e forma:SolidPeso molecolare:422.47HPK1-IN-3
HPK1-IN-3: Selective HPK1 inhibitor, ATP-competitive, IC50=0.25nM; boosts IL-2 in PBMCs, EC50=108nM.Formula:C23H22F4N6O2Colore e forma:SolidPeso molecolare:490.45SOS1-IN-9
SOS1-IN-9 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 116.5 nM).Formula:C22H28F3N5OColore e forma:SolidPeso molecolare:435.49KRAS inhibitor-41
CAS:<p>KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.</p>Formula:C30H37FN10OSColore e forma:SolidPeso molecolare:604.745JD118
CAS:<p>JD118 is an inhibitor of JNK. It effectively suppresses the activity of JNK1 and the expression of cJun (1 - 135).</p>Formula:C13H12N4S2Colore e forma:SolidPeso molecolare:288.391pan-KRAS-IN-6
CAS:<p>Pan-KRAS-IN-6 (compound 12) is a potent pan-KRAS inhibitor, with IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V.</p>Formula:C29H30ClF3N6O3SColore e forma:SolidPeso molecolare:635.10KRAS G12C inhibitor 44
KRAS G12C inhibitor 44: potent, oral, anti-cancer; halts cell growth in MIA PaCA-2, H358; effective in vivo. IC50: MIA-0.016μM, H358-0.028μM.Formula:C31H36ClFN6O2Colore e forma:SolidPeso molecolare:579.11JNK-1-IN-5
CAS:JNK-1-IN-5 (Compound 14) is a potent JNK1 inhibitor with sub-nanomolar efficacy. It effectively inhibits TGF-β-induced epithelial-mesenchymal transition and shows promise for research targeting JNK1 as an anti-pulmonary fibrosis agent.Formula:C23H21BrN6O3Colore e forma:SolidPeso molecolare:509.35510-Methoxy-canthin-6-one
CAS:10-Methoxy-canthin-6-one (Mtx-C) acts as a DNA damage inducer that embeds into DNA, promoting cell cycle arrest at the G2/M phase. This process triggers myeloid differentiation in acute myeloid leukemia cells (AML) and leukemia stem cells (LSC). Differentiation in AML and LSC cells is characterized by increased expression of myeloperoxidase, CD15, CD11b, and CD14, along with the activation of p38 MAPK. 10-Methoxy-canthin-6-one is utilized in the study of leukemia.Formula:C15H10N2O2Colore e forma:SolidPeso molecolare:250.25L 739749
CAS:L 739749 is a CAAX peptidomimetic. It is also an inhibitor of farnesyl-protein transferase.Formula:C24H41N3O6S2Purezza:98%Colore e forma:SolidPeso molecolare:531.73JNK-1-IN-4
CAS:<p>JNK-1-IN-4 (Compound E1) is an inhibitor of JNK, targeting JNK-1, JNK-2, and JNK-3 with IC50 values of 2.7, 19.0, and 9.0 nM, respectively. This compound inhibits the phosphorylation of c-Jun and reduces the expression of TGF-β1-induced EMT markers (such as fibronectin and α-SMA). JNK-1-IN-4 exhibits favorable pharmacokinetic properties with a bioavailability of 69%. Additionally, it demonstrates antifibrotic effects in a Bleomycin-induced mouse model of idiopathic pulmonary fibrosis.</p>Formula:C22H25BrN6O3Colore e forma:SolidPeso molecolare:501.38Anti-osteoporosis agent-11
CAS:<p>Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. It exhibits its most prominent effect by inhibiting osteoclast differentiation, with an IC50 value of 0.36 μM. Additionally, Anti-osteoporosis agent-11 suppresses osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking the RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.</p>Formula:C23H17NO2Se2Colore e forma:SolidPeso molecolare:497.31JD123
CAS:<p>JD123 inhibits the activity of JNK1 and the expression of cJun (1-135). It is an ATP-competitive inhibitor specific to p38-γ MAPK and has no effect on ERK1, ERK2, p38-α, p38-β, and p38-δ.</p>Formula:C12H11N5S2Colore e forma:SolidPeso molecolare:289.379KRAS ligand 5
CAS:KRAS ligand 5 acts as the target protein ligand for PROTACK-Ras Degrader-3, which specifically targets and degrades mutated KRAS proteins.Formula:C30H30F2N4O4Colore e forma:SolidPeso molecolare:548.58HPK1-IN-41
CAS:HPK1-IN-41 (compound Z389) functions as an HPK1 inhibitor, exhibiting an IC50 value of 0.21 nM [1].Formula:C28H33N5O2Colore e forma:SolidPeso molecolare:471.59Rho GTPase inhibitor 1
CAS:Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.Formula:C18H16N2OColore e forma:SolidPeso molecolare:276.33MEK4 inhibitor-2
CAS:MEK4 Inhibitor-2, a novel MEK4 inhibitor, demonstrates efficacy against pancreatic adenocarcinoma, exhibiting an IC50 value of 83 nM.Formula:C20H15FN4O3SColore e forma:SolidPeso molecolare:410.42XMU-MP-9
CAS:XMU-MP-9, a bifunctional compound, targets the C2 domain of Nedd4-1 and the allosteric site of K-Ras. It enhances the interaction and induces conformational changes within the Nedd4-1/K-Ras complex. Furthermore, XMU-MP-9 facilitates the ubiquitination and degradation of various K-Ras mutants and inhibits the proliferation of cells with these mutants. This compound is useful in cancer research.Formula:C19H13ClFN3OSColore e forma:SolidPeso molecolare:385.84Cot inhibitor-3
CAS:Cot inhibitor-3 (Compound 33) is an effective and selective cancerosaka thyroid (COT) kinase inhibitor with an IC50 of 4 nM. It can be used to prevent limpness caused by inflammation.Formula:C30H28N8OColore e forma:SolidPeso molecolare:516.60AZD4625
AZD4625 (Compound 21) is a selective, potent, orally active, covalent and mutagenic mutant GTPaseKRASG12C inhibitor.Formula:C24H21ClF2N4O3Colore e forma:SolidPeso molecolare:486.9SOS1 activator 2
CAS:<p>SOS1 activator 2 (Compound 65) is a benzothiazole derivative and an activator of SOS1. It demonstrates a high binding affinity for SOS1, with a Kd of 9 nM. By modulating the Ras-ERK signaling pathway, SOS1 activator 2 is suitable for tumor research.</p>Formula:C26H28ClFN6Colore e forma:SolidPeso molecolare:478.992EBI-907
CAS:EBI-907 is a potent, oral B-RafV600E inhibitor with an IC50 of 4.9 nM, over 10x stronger than Vemurafenib, and effective against key cancer kinases.Formula:C23H21ClF2N4O3SColore e forma:SolidPeso molecolare:506.95BMS-214662
CAS:BMS-214662 is a selective farnesyl transferase inhibitor with anti-tumor activity, used in research on pancreatic cancer, head and neck cancer, and lung cancer.Formula:C25H23N5O2S2Purezza:99.58% - 99.58%Colore e forma:SolidPeso molecolare:489.61p38 Kinase inhibitor 8
CAS:<p>p38 Kinase inhibitor 8 (Compound CCLXXVIII) is an orally active inhibitor targeting p38β and JNK2α2, with IC50 values of 6.3 nM and 53.6 nM, respectively. It has demonstrated anti-inflammatory effects in a rat model of collagen-induced arthritis.</p>Formula:C22H21FN6O2Colore e forma:SolidPeso molecolare:420.44Fulzerasib
CAS:<p>Fulzerasib is an orally active KRAS G12C inhibitor that covalently binds to cysteine residue on the protein, thereby inhibiting the growth of KRAS G12C mutant</p>Formula:C32H30ClFN6O4Purezza:98.04%Colore e forma:SolidPeso molecolare:617.07p38α inhibitor 8
CAS:p38α inhibitor8 (Compound 1) demonstrates inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.21 µM and 0.202 µM, respectively.Formula:C17H13FN6Colore e forma:SolidPeso molecolare:320.324G12Si-1
G12Si-1 selectively binds and inhibits K-Ras(G12S) to block oncogenic signaling and nucleotide exchange.Formula:C29H32ClN5O3Colore e forma:SolidPeso molecolare:534.05Everafenib
Everafenib: potent BRAF inhibitor, crosses blood-brain barrier, hinders MAPK, effective on V600EBRAF cells, outperforms other drugs in trials.Formula:C20H23ClFN5O2S2Colore e forma:SolidPeso molecolare:484.01p38 Kinase inhibitor 7
CAS:p38 Kinase inhibitor 7 (Comp:XXXIX) is an inhibitor of p38α, with an IC50 value of 5.25 nM. It also effectively suppresses TNFα production in THP-1 cells, demonstrating an IC50 of 5.88 nM.Formula:C22H25FN6OColore e forma:SolidPeso molecolare:408.472K-Ras-IN-4
CAS:K-Ras-IN-4 (compound CP163) is an inhibitor of K-Ras.Formula:C31H28F4N6O3SColore e forma:SolidPeso molecolare:640.65SOS1-IN-6
CAS:SOS1-IN-6 (compound 33-P1) is a potent inhibitor of SOS1, acting on SOS1-G12D (IC50: 14.9 nM) and SOS1-G12V (IC50: 73.3 nM).Formula:C26H28F3N3O2Colore e forma:SolidPeso molecolare:471.51HPK1-IN-21
HPK1-IN-21 is a potent, orally active HPK1 kinase inhibitor with a Ki value of 0.8 nM.Formula:C22H25ClFN5O2Colore e forma:SolidPeso molecolare:445.92p38 MAP Kinase-IN-1
CAS:p38 MAP Kinase-IN-1 (Compound 4) is an inhibitor of p38, suitable for studies related to inflammation and autoimmune responses.Formula:C20H19FN6OColore e forma:SolidPeso molecolare:378.403Casein kinase 1δ-IN-27
CAS:<p>Casein kinase1δ-IN-27 (Compound 8) is an inhibitor of casein kinase 1 (CK1), effectively inhibiting CK1α, CK1δ, CK1ε, and p38α with IC50 values of 22, 16.5, 9.41, and 14.8 nM, respectively. It also suppresses DUX4 expression, with an IC50 of 10 nM.</p>Formula:C21H19FN6Colore e forma:SolidPeso molecolare:374.414MEK1/2-IN-2
MEK1/2-IN-2 is a potent, ATP-competitive MEK1/2 inhibitor that exhibits equal inhibitory effects on wild-type MEK1/2 and a group of MEK1/2 mutant cells.Formula:C28H22ClFN6OColore e forma:SolidPeso molecolare:512.97HPK1-IN-16
CAS:HPK1-IN-16, a potent HPK1 inhibitor, useful for cancer research and treatment.Formula:C28H27FN4OColore e forma:SolidPeso molecolare:454.54HPK1-IN-31
HPK1-IN-31 inhibitor with an IC 50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunotherapy .Formula:C30H33N7O3Colore e forma:SolidPeso molecolare:539.63
